A multicenter retrospective study of PD-1 blockade plus chemotherapy as first-line therapy in advanced hepatoid adenocarcinoma of the stomach
Patients with HAS can derive survival benefits from first-line treatment with PD-1 blockade combined with chemotherapy, and the treatment is well tolerated. Furthermore, this pathological subtype may serve as a predictive indicator of favorable efficacy for PD-1 blockade, regardless of the patients' programmed death-ligand 1 combined positive score.
Authors
- Xiao Sun (ORCID: https://orcid.org/0000-0002-6860-747X)
- Xiaojun Xiang (ORCID: https://orcid.org/0000-0002-8734-584X)
- Jianhua Wu (ORCID: https://orcid.org/0000-0001-6093-599X)
- Gang Su
- Yan He (ORCID: https://orcid.org/0000-0001-8074-0313)
- Ling Zhou (ORCID: https://orcid.org/0000-0001-6335-5472)
- Jinbo Zhan (ORCID: https://orcid.org/0009-0000-2626-4870)
- Jingru Wang (ORCID: https://orcid.org/0009-0006-8683-1121)
- Rao Zhen
Institutions
- Nanchang University (CN)
- Sun Yat-sen University (CN)
- Soochow University (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
- Sun Yat-sen University Cancer Center (CN)
- First Affiliated Hospital of Soochow University (CN)
- First Affiliated Hospital of Nanchang University (CN)
- State Key Laboratory of Oncology in South China
- Southern Medical University (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1093/oncolo/oyaf312
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangxi Province